Mesa Laboratories (MLAB) 10-Q 31 Oct 18 2019 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Sep. 30, 2018	Oct. 26, 2018
Document Information [Line Items]
Entity Registrant Name	MESA LABORATORIES INC /CO
Entity Central Index Key	724,004
Trading Symbol	mlab
Current Fiscal Year End Date	--03-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		3,852,835
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2,019
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2018	Mar. 31, 2018
ASSETS
Cash and cash equivalents	$ 5,625	$ 5,469
Accounts receivable, less allowances of $128 and $179, respectively	13,242	14,302
Inventories, net	8,336	9,228
Prepaid income taxes	4,165	273
Prepaid expenses and other	2,223	782
Assets held for sale		1,934
Total current assets	33,591	31,988
Property, plant and equipment, net	23,235	23,593
Deferred taxes	120	127
Intangibles, net	38,260	42,850
Goodwill	65,082	65,543
Total assets	160,288	164,101
LIABILITIES AND STOCKHOLDERS’ EQUITY
Accounts payable	2,295	2,380
Accrued salaries and payroll taxes	4,607	4,284
Current portion of long-term debt	1,875	1,625
Unearned revenues	3,744	3,921
Current portion of contingent consideration	46	709
Income taxes payable		1,008
Estimated legal liability	3,300
Other accrued expenses	3,665	3,363
Total current liabilities	19,532	17,290
Deferred income taxes	2,532	2,621
Long-term debt, net of debt issuance costs and current portion	31,188	44,635
Other long-term liabilities	133	194
Total liabilities	53,385	64,740
Stockholders’ equity:
Common stock, no par value; authorized 25,000,000 shares; issued and outstanding, 3,852,747 and 3,801,439 shares, respectively	35,421	30,516
Retained earnings	72,279	68,281
Accumulated other comprehensive (loss) income	(797)	564
Total stockholders’ equity	106,903	99,361
Total liabilities and stockholders’ equity	$ 160,288	$ 164,101

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ / shares in Thousands, $ in Thousands	Sep. 30, 2018	Mar. 31, 2018
Allowance for doubtful accounts receivable	$ 128	$ 179
Common stock, par value (in dollars per share)	$ 0	$ 0
Common stock, shares authorized (in shares)	25,000,000	25,000,000
Common stock, shares issued (in shares)	3,852,747	3,801,439
Common stock, shares outstanding (in shares)	3,852,747	3,801,439

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenues	$ 24,865	$ 22,954	$ 50,007	$ 45,627
Cost of revenues	10,288	9,721	20,339	19,723
Gross profit	14,577	13,233	29,668	25,904
Operating expenses:
Selling	1,804	2,288	3,694	4,967
General and administrative	7,493	6,412	15,093	13,269
Research and development	842	885	1,679	2,038
Estimated legal settlement	3,300		3,300
Total operating expenses	13,439	9,585	23,766	20,274
Operating income	1,138	3,648	5,902	5,630
Other (income) expense, net	(168)	542	196	1,221
Earnings before income taxes	1,306	3,106	5,706	4,409
Income tax expense	312	753	482	539
Net income	$ 994	$ 2,353	$ 5,224	$ 3,870
Earnings per share:
Basic (in dollars per share)	$ 0.26	$ 0.63	$ 1.36	$ 1.03
Diluted (in dollars per share)	$ 0.25	$ 0.60	$ 1.30	$ 0.98
Weighted-average common shares outstanding:
Basic (in shares)	3,850	3,764	3,833	3,754
Diluted (in shares)	4,046	3,935	4,029	3,934

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Net income	$ 994	$ 2,353	$ 5,224	$ 3,870
Other comprehensive (loss) income, net of tax:
Foreign currency translation adjustments	(49)	948	(1,361)	1,699
Comprehensive income	$ 945	$ 3,301	$ 3,863	$ 5,569

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Cash flows from operating activities:
Net income	$ 5,224	$ 3,870
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	4,889	4,531
Stock-based compensation	1,729	985
Gain on disposition of assets	(288)	(116)
Deferred taxes		144
Foreign currency adjustments		(533)
Adjustment to contingent consideration	(33)	300
Other	111	55
Cash provided by changes in operating assets and liabilities:
Accounts receivable, net	643	2,132
Inventories, net	1,022	960
Prepaid expenses and other current assets	(1,301)	(2,241)
Accounts payable	(70)	(132)
Accrued liabilities and taxes payable	(866)	(1,819)
Unearned revenues	(177)	(312)
Contingent consideration	(683)	(456)
Net cash provided by operating activities	10,200	7,368
Cash flows from investing activities:
Acquisitions		(62)
Proceeds from sale of assets	2,222	1,133
Purchases of property, plant and equipment	(849)	(2,012)
Net cash provided by (used in) investing activities	1,373	(941)
Cash flows from financing activities:
Proceeds from the issuance of debt		4,000
Payments on debt	(13,250)	(7,000)
Dividends	(1,226)	(1,201)
Proceeds from the exercise of stock options	3,176	2,064
Net cash used in financing activities	(11,300)	(2,137)
Effect of exchange rate changes on cash and cash equivalents	(117)	158
Net increase in cash and cash equivalents	156	4,448
Cash and cash equivalents at the beginning of the period	5,469	5,820
Cash and cash equivalents at the end of the period	5,625	10,268
Cash paid for:
Income taxes paid	5,310	2,446
Interest paid	$ 938	$ 1,007

Note 1 - Description of Busines

Note 1 - Description of Business and Summary of Significant Accounting Policies	6 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]	Note 1 . Description of Business and Summary of Significant Accounting Policies Description of Business In this quarterly report on Form 10 We pursue a strategy of focusing primarily on quality control products and services which are sold into niche markets that are driven by regulatory requirements. We prefer markets in which we can establish a strong presence and achieve high gross margins. We are organized into four nine Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission. In the opinion of management, such unaudited information includes all adjustments, consisting of normal recurring adjustments necessary for a fair presentation of our financial position and results of operations. The results of operations for the interim periods are not may not 10 March 31, 2018. Recently Issued Accounting Pronouncements In August 2018, No. 33 10532 3 04 X December 31, 2018. 10 In February 2016, 2016 02, Leases (Topic 842 12 not not Recently Adopted Accounting Pronouncements During the three September 30, 2018, 2018 15 Intangibles – Goodwill and Other Internal-Use Software: Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract 2018 15” 2018 15 $144 three September 30, 2018 Effective April 1, 2018, 2014 09 Revenue from Contracts with Customers (Topic 606 606” 606 not 2. In March 2018, 2018 05, No. 118. may 7.

Note 2 - Revenue Recognition

Note 2 - Revenue Recognition	6 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	Note 2. We design, manufacture, market, sell, and maintain quality control instruments, consumables, and services driven primarily by the regulatory requirements of niche markets. Our consumables, such as biological indicator test strips and packaging materials, are typically used on a standalone basis; however, some, such as calibration solutions, are also critical to the ongoing use of our instruments. Instruments sales, such as medical meters, wireless sensors, and data loggers are generally driven by our acquisition of new customers, growth of existing customers, or customer replacement of existing equipment. We generally generate service revenues from three 1 2 3 Substantially all of our revenues and related receivables are generated from contracts with customers that are 12 no 60 Our performance obligations related to the sale of instruments and consumables generally consist of the promise to sell tangible goods to distributors or end users. Ownership of these goods is typically transferred at time of shipment, at which point we have satisfied our performance obligation and we recognize revenue. Our performance obligations related to services may may no may may not The following tables present disaggregated revenues for the three six September 30, 2018 September 30, 2017, Three Months Ended September 30, 2018 Sterilization and Disinfection Control Instruments Cold Chain Monitoring Cold Chain Packaging Total Discrete Revenues Consumables $ 9,093 $ 641 $ 127 $ 1,533 $ 11,394 Hardware 704 5,672 1,193 -- 7,569 Services 291 2,391 698 96 3,476 Contracted Revenues Services 1,494 -- 932 -- 2,426 Total Revenues $ 11,582 $ 8,704 $ 2,950 $ 1,629 $ 24,865 Three Months Ended September 30, 2017 Sterilization and Disinfection Control Instruments Cold Chain Monitoring Cold Chain Packaging Total Discrete Revenues Consumables $ 8,206 $ 553 $ 80 $ 1,599 $ 10,438 Hardware 221 5,230 1,272 -- 6,723 Services 312 2,200 488 236 3,236 Contracted Revenues Services 1,246 -- 1,311 -- 2,557 Total Revenues $ 9,985 $ 7,983 $ 3,151 $ 1,835 $ 22,954 Six Months Ended September 30, 2018 Sterilization and Disinfection Control Instruments Cold Chain Monitoring Cold Chain Packaging Total Discrete Revenues Consumables $ 18,663 $ 1,433 $ 191 $ 3,273 $ 23,560 Hardware 908 11,212 2,533 -- 14,653 Services 642 4,790 1,241 196 6,869 Contracted Revenues Services 2,717 -- 2,208 -- 4,925 Total Revenues $ 22,930 $ 17,435 $ 6,173 $ 3,469 $ 50,007 Six Months Ended September 30, 2017 Sterilization and Disinfection Control Instruments Cold Chain Monitoring Cold Chain Packaging Total Discrete Revenues Consumables $ 16,875 $ 1,497 $ 111 $ 2,486 $ 20,969 Hardware 354 10,770 2,444 -- 13,568 Services 521 4,319 1,214 319 6,373 Contracted Revenues Services 2,418 -- 2,299 -- 4,717 Total Revenues $ 20,168 $ 16,586 $ 6,068 $ 2,805 $ 45,627 Contract Balances Our contracts have varying payment terms and conditions. Some customers prepay for services, resulting in unearned revenues or customer deposits, called contract liabilities, which are included within other accrued expenses and unearned revenues in the accompanying condensed consolidated balance sheets. Contract assets would exist when sales are recorded (i.e. the control of the goods or services has been transferred to the customer), but customer payment is contingent on a future event besides the passage of time (such as satisfaction of additional performance obligations). We do not not A summary of contract liabilities is as follows: Contract liabilities balance as of March 31, 2018 $ 4,147 Prior year liabilities recognized in revenues during the six months ended September 30, 2018 (2,485 ) Contract liabilities added during the six months ended September 30, 2018, net of revenues recognized 2,756 Contract liabilities balance as of September 30, 2018 $ 4,418

Note 3 - Inventories

Note 3 - Inventories	6 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Inventory Disclosure [Text Block]	Note 3 . Inventories Inventories consist of the following: September 30, 2018 March 31, 2018 Raw materials $ 7,895 $ 9,059 Work-in-process 482 380 Finished goods 3,378 3,152 Less: reserve (3,419 ) (3,363 ) Inventories, net $ 8,336 $ 9,228

Note 4 - Facility Relocation

Note 4 - Facility Relocation	6 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Restructuring and Related Activities Disclosure [Text Block]	Note 4 . Facility Relocation In August 2016, two March 2017 June 30, 2018. $1,584 Facility relocation amounts accrued and paid for the six September 30, 2018 Balance at March 31, 2018 $ 408 Facility relocation expense 17 Cash payments (425 ) Balance at September 30, 2018 $ -- We completed the sale of our old Bozeman facility during the period ended September 30, 2018, $2,222 $288,

Note 5 - Long-term Debt

Note 5 - Long-term Debt	6 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 5 . Long-T erm Debt Long-term debt consists of the following: September 30, 2018 March 31, 2018 Line of credit (3.625%, as of September 30, 2018) $ 15,500 $ 28,000 Term loan (3.750% as of September 30, 2018) 17,875 18,625 Less: discount (312 ) (365 ) Less: current portion (1,875 ) (1,625 ) Long-term portion $ 31,188 $ 44,635 On March 1, 2017, five $80,000 $20,000 $2,500 four $100,000. Line of Credit and Term Loan indebtedness bears interest at either: ( 1 1.50% 2.50%; 2 0.5%. 0.15% 0.35%. The Credit Facility is secured by all of our assets and requires us to maintain a ratio of funded debt to our trailing four 3.0 1.0, may $20,000, 3.50 1.00 four 3.25 1.00 four 1.25 1.0. September 30, 2018. As of September 30, 2018, Year ending March 31, 2019 $ 875 2020 2,125 2021 2,625 2022 27,750 Total $ 33,375

Note 6 - Stock-based Compensati

Note 6 - Stock-based Compensation	6 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	Note 6 . Stock-B ased Compensation During the six September 30, 2018, 15,919 $151.54 five six September 30, 2018, 1,720 185 During the six September 30, 2018, 11,385 $192.99 three April 1, 2018 March 31, 2021, June 15, 2021. 0 400 not no During the six September 30, 2018, 24,940 $53.56 $143.36 five Amounts recognized in the condensed consolidated financial statements related to stock-based compensation are as follows: Three Months Ended September 30, Six Months Ended September 30, 2018 2017 2018 2017 Stock-based compensation expense $ 990 $ 445 $ 1,729 $ 985 Amount of income tax expense (benefit) recognized in earnings 38 (108 ) (858 ) (120 ) Stock-based compensation, net of tax $ 1,028 $ 337 $ 871 $ 865 Benefit to earnings per share Basic $ 0.27 $ 0.09 $ 0.23 $ 0.23 Diluted 0.25 0.09 0.22 0.22 Stock-based compensation expense is included in cost of revenues, selling, general and administrative, and research and development expense in the accompanying condensed consolidated statements of income. The following is a summary of stock option and non-vested stock award activity for the six September 30, 2018 ( Stock Options Non-Vested Stock Awards Number of Shares Weighted- Average Exercise Price per Share Number of Shares Weighted- Average Grant Date Fair Value Outstanding at March 31, 2018 458 $ 86.38 9 $ 125.68 Awards granted 25 143.36 27 168.82 Awards forfeited or expired (25 ) 96.51 -- 142.20 Awards exercised or vested (52 ) 68.98 (2 ) 151.18 Outstanding as of September 30, 2018 406 $ 91.53 34 $ 161.30 Exercisable at September 30, 2018 157 We issue shares in connection with stock-based compensation pursuant to the Mesa Laboratories, Inc. 2014 “2014 2014 five one 2014 1,100,000 595,729 September 30, 2018.

Note 7 - Income Taxes

Note 7 - Income Taxes	6 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Income Tax Disclosure [Text Block]	Note 7 . Income Taxes For interim income tax reporting, we estimate our annual effective tax rate and apply this effective tax rate to our year-to-date pre-tax income. Each quarter, the estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. Additionally, the tax effects of significant unusual or infrequently occurring items are recognized as discrete items in the interim period in which the events occur. The impact of changes in tax laws or rates on deferred tax amounts, excess benefits from stock-based compensation, impairments of non-deductible goodwill, and changes in tax reserves resulting from the finalization of tax audits or reviews are examples of significant unusual or infrequently occurring items that are recognized as discrete items in the interim period in which the event occurs. There is a potential for volatility of the effective tax rate due to several factors, including excess benefits from stock-based compensation, changes in the mix of the pre-tax income and the jurisdictions to which it relates, changes in tax laws and foreign tax holidays, settlement with taxing authorities, and foreign currency fluctuations. On December 22, 2017, 34 21 December 31, 2017, one 199 162 Shortly thereafter, the Securities and Exchange Commission staff issued SAB 118, 740 740 one Accordingly, as of September 30, 2018, not March 31, 2018, one $220. $279. $59. March 31, 2018. Our effective income tax rate was 23.9 24.2 three September 30, 2018 September 30, 2017, 8.4 12.2 six September 30, 2018 September 30, 2017, six September 30, 2018 21 Since we are subject to audit by various taxing authorities, it is reasonably possible that the amount of unrecognized tax benefits will change during the next 12 not 12

Note 8 - Earnings Per Share

Note 8 - Earnings Per Share	6 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Earnings Per Share [Text Block]	Note 8 . Earnings Per Share Basic earnings per share is computed by dividing net income by the weighted-average number of common shares outstanding during the reporting period. Diluted earnings per share (“diluted EPS”) is computed similarly to basic earnings per share, except that it includes the potential dilution that could occur if dilutive securities were exercised. Potentially dilutive securities include common shares related to stock options and non-vested stock awards (collectively “stock awards”). Stock awards are excluded from the calculation of diluted EPS in the event that they are subject to performance conditions or are antidilutive. The following table presents a reconciliation of the denominators used in the computation of basic and diluted earnings per share (shares in thousands): Three Months Ended September 30, Six Months Ended September 30, 2018 2017 2018 2017 Net income available for shareholders $ 994 $ 2,353 $ 5,224 $ 3,870 Weighted average outstanding shares of common stock 3,850 3,764 3,833 3,754 Dilutive effect of stock options 188 171 183 180 Dilutive effect of non-vested shares 8 -- 13 -- Fully diluted shares 4,046 3,935 4,029 3,934 Basic $ 0.26 $ 0.63 $ 1.36 $ 1.03 Diluted $ 0.25 $ 0.60 $ 1.30 $ 0.98 The following stock awards were excluded from the calculation of diluted EPS: Three Months Ended September 30, Six Months Ended September 30, 2018 2017 2018 2017 Stock awards that were anti-dilutive 1 111 24 111 Stock awards subject to performance conditions 11 - 7 - Total stock awards excluded from diluted EPS 12 111 31 111

Note 9 - Commitments and Contin

Note 9 - Commitments and Contingencies	6 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 9 . Commitments and Contingencies In February 2018, June 2018, three September 30, 2018, $3,300 may

Note 10 - Segment Information

Note 10 - Segment Information	6 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	Note 1 0 . S egment Information We have four Three Months Ended September 30, 2018 Sterilization and Disinfection Control Instruments Cold Chain Monitoring Cold Chain Packaging Total Revenues $ 11,582 $ 8,704 $ 2,950 $ 1,629 $ 24,865 Gross profit $ 7,972 $ 5,354 $ 1,164 $ 87 $ 14,577 Reconciling items (1) (13,271 ) Earnings before income taxes $ 1,306 Three Months Ended September 30, 2017 Sterilization and Disinfection Control Instruments Cold Chain Monitoring Cold Chain Packaging Total Revenues $ 9,985 $ 7,983 $ 3,151 $ 1,835 $ 22,954 Gross profit $ 6,822 $ 4,963 $ 1,193 $ 255 $ 13,233 Reconciling items (1) (10,127 ) Earnings before income taxes $ 3,106 Six Months Ended September 30, 2018 Sterilization and Disinfection Control Instruments Cold Chain Monitoring Cold Chain Packaging Total Revenues $ 22,930 $ 17,435 $ 6,173 $ 3,469 $ 50,007 Gross profit $ 15,784 $ 10,987 $ 2,628 $ 269 $ 29,668 Reconciling items (1) (23,962 ) Earnings before income taxes $ 5,706 Six Months Ended September 30, 2017 Sterilization and Disinfection Control Instruments Cold Chain Monitoring Cold Chain Packaging Total Revenues $ 20,168 $ 16,586 $ 6,068 $ 2,805 $ 45,627 Gross profit $ 13,542 $ 9,871 $ 2,087 $ 404 $ 25,904 Reconciling items (1) (21,495 ) Earnings before income taxes $ 4,409 ( 1 Reconciling items include selling, general and administrative, research and development, estimated legal settlement, and other (income) expenses September 30, 2018 March 31, 2018 Total assets Sterilization and Disinfection Control $ 77,817 $ 83,452 Instruments 30,616 33,479 Cold Chain Monitoring 29,957 30,796 Cold Chain Packaging 6,993 7,091 Corporate and administrative 14,905 9,283 Total $ 160,288 $ 164,101 As of September 30, 2018, $6,203, $6,667 $15,585 Revenues from external customers are attributed to individual countries based upon locations to which the product is shipped or exported, as follows: Three Months Ended September 30, Six Months Ended September 30, 2018 2017 2018 2017 United States $ 16,617 $ 14,432 $ 32,165 $ 27,443 Foreign 8,248 8,522 17,842 18,184 Total $ 24,865 $ 22,954 $ 50,007 $ 45,627 No 10

Note 11 - Subsequent Event

Note 11 - Subsequent Event	6 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Subsequent Events [Text Block]	Note 1 1 . Subsequent Event In October 2018, $0.16 December 17, 2018 November 30, 2018

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission. In the opinion of management, such unaudited information includes all adjustments, consisting of normal recurring adjustments necessary for a fair presentation of our financial position and results of operations. The results of operations for the interim periods are not may not 10 March 31, 2018.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements In August 2018, No. 33 10532 3 04 X December 31, 2018. 10 In February 2016, 2016 02, Leases (Topic 842 12 not not Recently Adopted Accounting Pronouncements During the three September 30, 2018, 2018 15 Intangibles – Goodwill and Other Internal-Use Software: Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract 2018 15” 2018 15 $144 three September 30, 2018 Effective April 1, 2018, 2014 09 Revenue from Contracts with Customers (Topic 606 606” 606 not 2. In March 2018, 2018 05, No. 118. may 7.

Note 2 - Revenue Recognition (T

Note 2 - Revenue Recognition (Tables)	6 Months Ended
	Sep. 30, 2018
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended September 30, 2018 Sterilization and Disinfection Control Instruments Cold Chain Monitoring Cold Chain Packaging Total Discrete Revenues Consumables $ 9,093 $ 641 $ 127 $ 1,533 $ 11,394 Hardware 704 5,672 1,193 -- 7,569 Services 291 2,391 698 96 3,476 Contracted Revenues Services 1,494 -- 932 -- 2,426 Total Revenues $ 11,582 $ 8,704 $ 2,950 $ 1,629 $ 24,865 Three Months Ended September 30, 2017 Sterilization and Disinfection Control Instruments Cold Chain Monitoring Cold Chain Packaging Total Discrete Revenues Consumables $ 8,206 $ 553 $ 80 $ 1,599 $ 10,438 Hardware 221 5,230 1,272 -- 6,723 Services 312 2,200 488 236 3,236 Contracted Revenues Services 1,246 -- 1,311 -- 2,557 Total Revenues $ 9,985 $ 7,983 $ 3,151 $ 1,835 $ 22,954 Six Months Ended September 30, 2018 Sterilization and Disinfection Control Instruments Cold Chain Monitoring Cold Chain Packaging Total Discrete Revenues Consumables $ 18,663 $ 1,433 $ 191 $ 3,273 $ 23,560 Hardware 908 11,212 2,533 -- 14,653 Services 642 4,790 1,241 196 6,869 Contracted Revenues Services 2,717 -- 2,208 -- 4,925 Total Revenues $ 22,930 $ 17,435 $ 6,173 $ 3,469 $ 50,007 Six Months Ended September 30, 2017 Sterilization and Disinfection Control Instruments Cold Chain Monitoring Cold Chain Packaging Total Discrete Revenues Consumables $ 16,875 $ 1,497 $ 111 $ 2,486 $ 20,969 Hardware 354 10,770 2,444 -- 13,568 Services 521 4,319 1,214 319 6,373 Contracted Revenues Services 2,418 -- 2,299 -- 4,717 Total Revenues $ 20,168 $ 16,586 $ 6,068 $ 2,805 $ 45,627
Contract with Customer, Asset and Liability [Table Text Block]	Contract liabilities balance as of March 31, 2018 $ 4,147 Prior year liabilities recognized in revenues during the six months ended September 30, 2018 (2,485 ) Contract liabilities added during the six months ended September 30, 2018, net of revenues recognized 2,756 Contract liabilities balance as of September 30, 2018 $ 4,418

Note 3 - Inventories (Tables)

Note 3 - Inventories (Tables)	6 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Inventory, Current [Table Text Block]	September 30, 2018 March 31, 2018 Raw materials $ 7,895 $ 9,059 Work-in-process 482 380 Finished goods 3,378 3,152 Less: reserve (3,419 ) (3,363 ) Inventories, net $ 8,336 $ 9,228

Note 4 - Facility Relocation (T

Note 4 - Facility Relocation (Tables)	6 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]	Balance at March 31, 2018 $ 408 Facility relocation expense 17 Cash payments (425 ) Balance at September 30, 2018 $ --

Note 5 - Long-term Debt (Tables

Note 5 - Long-term Debt (Tables)	6 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Debt [Table Text Block]	September 30, 2018 March 31, 2018 Line of credit (3.625%, as of September 30, 2018) $ 15,500 $ 28,000 Term loan (3.750% as of September 30, 2018) 17,875 18,625 Less: discount (312 ) (365 ) Less: current portion (1,875 ) (1,625 ) Long-term portion $ 31,188 $ 44,635
Schedule of Maturities of Long-term Debt [Table Text Block]	Year ending March 31, 2019 $ 875 2020 2,125 2021 2,625 2022 27,750 Total $ 33,375

Note 6 - Stock-based Compensa_2

Note 6 - Stock-based Compensation (Tables)	6 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Three Months Ended September 30, Six Months Ended September 30, 2018 2017 2018 2017 Stock-based compensation expense $ 990 $ 445 $ 1,729 $ 985 Amount of income tax expense (benefit) recognized in earnings 38 (108 ) (858 ) (120 ) Stock-based compensation, net of tax $ 1,028 $ 337 $ 871 $ 865 Benefit to earnings per share Basic $ 0.27 $ 0.09 $ 0.23 $ 0.23 Diluted 0.25 0.09 0.22 0.22
Share-based Compensation, Activity [Table Text Block]	Stock Options Non-Vested Stock Awards Number of Shares Weighted- Average Exercise Price per Share Number of Shares Weighted- Average Grant Date Fair Value Outstanding at March 31, 2018 458 $ 86.38 9 $ 125.68 Awards granted 25 143.36 27 168.82 Awards forfeited or expired (25 ) 96.51 -- 142.20 Awards exercised or vested (52 ) 68.98 (2 ) 151.18 Outstanding as of September 30, 2018 406 $ 91.53 34 $ 161.30 Exercisable at September 30, 2018 157

Note 8 - Earnings Per Share (Ta

Note 8 - Earnings Per Share (Tables)	6 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended September 30, Six Months Ended September 30, 2018 2017 2018 2017 Net income available for shareholders $ 994 $ 2,353 $ 5,224 $ 3,870 Weighted average outstanding shares of common stock 3,850 3,764 3,833 3,754 Dilutive effect of stock options 188 171 183 180 Dilutive effect of non-vested shares 8 -- 13 -- Fully diluted shares 4,046 3,935 4,029 3,934 Basic $ 0.26 $ 0.63 $ 1.36 $ 1.03 Diluted $ 0.25 $ 0.60 $ 1.30 $ 0.98
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended September 30, Six Months Ended September 30, 2018 2017 2018 2017 Stock awards that were anti-dilutive 1 111 24 111 Stock awards subject to performance conditions 11 - 7 - Total stock awards excluded from diluted EPS 12 111 31 111

Note 10 - Segment Information (

Note 10 - Segment Information (Tables)	6 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Three Months Ended September 30, 2018 Sterilization and Disinfection Control Instruments Cold Chain Monitoring Cold Chain Packaging Total Revenues $ 11,582 $ 8,704 $ 2,950 $ 1,629 $ 24,865 Gross profit $ 7,972 $ 5,354 $ 1,164 $ 87 $ 14,577 Reconciling items (1) (13,271 ) Earnings before income taxes $ 1,306 Three Months Ended September 30, 2017 Sterilization and Disinfection Control Instruments Cold Chain Monitoring Cold Chain Packaging Total Revenues $ 9,985 $ 7,983 $ 3,151 $ 1,835 $ 22,954 Gross profit $ 6,822 $ 4,963 $ 1,193 $ 255 $ 13,233 Reconciling items (1) (10,127 ) Earnings before income taxes $ 3,106 Six Months Ended September 30, 2018 Sterilization and Disinfection Control Instruments Cold Chain Monitoring Cold Chain Packaging Total Revenues $ 22,930 $ 17,435 $ 6,173 $ 3,469 $ 50,007 Gross profit $ 15,784 $ 10,987 $ 2,628 $ 269 $ 29,668 Reconciling items (1) (23,962 ) Earnings before income taxes $ 5,706 Six Months Ended September 30, 2017 Sterilization and Disinfection Control Instruments Cold Chain Monitoring Cold Chain Packaging Total Revenues $ 20,168 $ 16,586 $ 6,068 $ 2,805 $ 45,627 Gross profit $ 13,542 $ 9,871 $ 2,087 $ 404 $ 25,904 Reconciling items (1) (21,495 ) Earnings before income taxes $ 4,409
Reconciliation of Assets from Segment to Consolidated [Table Text Block]	September 30, 2018 March 31, 2018 Total assets Sterilization and Disinfection Control $ 77,817 $ 83,452 Instruments 30,616 33,479 Cold Chain Monitoring 29,957 30,796 Cold Chain Packaging 6,993 7,091 Corporate and administrative 14,905 9,283 Total $ 160,288 $ 164,101
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]	Three Months Ended September 30, Six Months Ended September 30, 2018 2017 2018 2017 United States $ 16,617 $ 14,432 $ 32,165 $ 27,443 Foreign 8,248 8,522 17,842 18,184 Total $ 24,865 $ 22,954 $ 50,007 $ 45,627

Note 1 - Description of Busin_2

Note 1 - Description of Business and Summary of Significant Accounting Policies (Details Textual) $ in Thousands	6 Months Ended
	Sep. 30, 2018USD ($)
Number of Operating Segments	4
Enterprise Resource Planning System Implementation Costs [Member]
Capitalized Contract Cost, Gross	$ 144

Note 2 - Revenue Recognition (D

Note 2 - Revenue Recognition (Details Textual) $ in Thousands	Sep. 30, 2018USD ($)
Contract with Customer, Asset, Net, Total	$ 0

Note 2 - Revenue Recognition -

Note 2 - Revenue Recognition - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenues	$ 24,865	$ 22,954	$ 50,007	$ 45,627
Consumables [Member] | Transferred at Point in Time [Member]
Revenues	11,394	10,438	23,560	20,969
Hardware [Member] | Transferred at Point in Time [Member]
Revenues	7,569	6,723	14,653	13,568
Service [Member] | Transferred at Point in Time [Member]
Revenues	3,476	3,236	6,869	6,373
Service [Member] | Transferred over Time [Member]
Revenues	2,426	2,557	4,925	4,717
Sterilzation and Disinfection Control [Member]
Revenues	11,582	9,985	22,930	20,168
Sterilzation and Disinfection Control [Member] | Consumables [Member] | Transferred at Point in Time [Member]
Revenues	9,093	8,206	18,663	16,875
Sterilzation and Disinfection Control [Member] | Hardware [Member] | Transferred at Point in Time [Member]
Revenues	704	221	908	354
Sterilzation and Disinfection Control [Member] | Service [Member] | Transferred at Point in Time [Member]
Revenues	291	312	642	521
Sterilzation and Disinfection Control [Member] | Service [Member] | Transferred over Time [Member]
Revenues	1,494	1,246	2,717	2,418
Instruments [Member]
Revenues	8,704	7,983	17,435	16,586
Instruments [Member] | Consumables [Member] | Transferred at Point in Time [Member]
Revenues	641	553	1,433	1,497
Instruments [Member] | Hardware [Member] | Transferred at Point in Time [Member]
Revenues	5,672	5,230	11,212	10,770
Instruments [Member] | Service [Member] | Transferred at Point in Time [Member]
Revenues	2,391	2,200	4,790	4,319
Instruments [Member] | Service [Member] | Transferred over Time [Member]
Revenues
Cold Chain Monitoring [Member]
Revenues	2,950	3,151	6,173	6,068
Cold Chain Monitoring [Member] | Consumables [Member] | Transferred at Point in Time [Member]
Revenues	127	80	191	111
Cold Chain Monitoring [Member] | Hardware [Member] | Transferred at Point in Time [Member]
Revenues	1,193	1,272	2,533	2,444
Cold Chain Monitoring [Member] | Service [Member] | Transferred at Point in Time [Member]
Revenues	698	488	1,241	1,214
Cold Chain Monitoring [Member] | Service [Member] | Transferred over Time [Member]
Revenues	932	1,311	2,208	2,299
Cold Chain Packaging [Member]
Revenues	1,629	1,835	3,469	2,805
Cold Chain Packaging [Member] | Consumables [Member] | Transferred at Point in Time [Member]
Revenues	1,533	1,599	3,273	2,486
Cold Chain Packaging [Member] | Hardware [Member] | Transferred at Point in Time [Member]
Revenues
Cold Chain Packaging [Member] | Service [Member] | Transferred at Point in Time [Member]
Revenues	96	236	196	319
Cold Chain Packaging [Member] | Service [Member] | Transferred over Time [Member]
Revenues

Note 2 - Revenue Recognition _2

Note 2 - Revenue Recognition - Contract Liabilities (Details) $ in Thousands	6 Months Ended
	Sep. 30, 2018USD ($)
Contract liabilities balance as of March 31, 2018	$ 4,147
Prior year liabilities recognized in revenues during the six months ended September 30, 2018	(2,485)
Contract liabilities added during the six months ended September 30, 2018, net of revenues recognized	2,756
Contract liabilities balance as of September 30, 2018	$ 4,418

Note 3 - Inventories - Summary

Note 3 - Inventories - Summary of Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Mar. 31, 2018
Raw materials	$ 7,895	$ 9,059
Work-in-process	482	380
Finished goods	3,378	3,152
Less: reserve	(3,419)	(3,363)
Inventories, net	$ 8,336	$ 9,228

Note 4 - Facility Relocation (D

Note 4 - Facility Relocation (Details Textual) - USD ($) $ in Thousands	6 Months Ended
	Sep. 30, 2018	Jun. 30, 2018
Bozeman [Member]
Proceeds from Sale of Productive Assets, Total	$ 2,222
Bozeman [Member] | Other Nonoperating Income (Expense) [Member]
Gain (Loss) on Disposition of Assets for Financial Service Operations, Total	$ 288
Relocation of Omaha and Traverse City Biological Indicator Manufacturing Facilities [Member]
Restructuring and Related Cost, Expected Cost, Total		$ 1,584

Note 4 - Facility Relocation -

Note 4 - Facility Relocation - Facility Relocation Costs (Details) - Relocation of Omaha and Traverse City Biological Indicator Manufacturing Facilities [Member] $ in Thousands	6 Months Ended
	Sep. 30, 2018USD ($)
Balance at March 31, 2018	$ 408
Facility relocation expense	17
Cash payments	(425)
Balance at September 30, 2018

Note 5 - Long-term Debt (Detail

Note 5 - Long-term Debt (Details Textual) $ in Millions	Mar. 01, 2017USD ($)
Credit Facility [Member]
Debt Instrument Convenant, Maximum Leverage Ration, During the Initial Holiday Period	3.5
Debt Instrument Covenant, Maximum Leverage Ratio, Immediately Following the Initial Holiday Period	3.25
Debt Instrument Covenant, Fixed Charge Coverage Ratio	1.25
Credit Facility [Member] | After March 31, 2016 [Member]
Debt Instrument Covenant, Ratio of Funded Debt to Consolidated EBITDA	3
Credit Facility [Member] | Term Loan [Member]
Long-term Debt, Gross	$ 20
Line of Credit [Member]
Long-term Debt, Gross	$ 20
Line of Credit [Member] | Debt Instrument, Variable Rate Base CBFR Using One Month LIBOR [Member]
Debt Instrument, Basis Spread on Variable Rate Used to Calculate Commercial Bank Floating Rate	0.50%
Line of Credit [Member] | Minimum [Member]
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.15%
Line of Credit [Member] | Minimum [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate	1.50%
Line of Credit [Member] | Maximum [Member]
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.35%
Line of Credit [Member] | Maximum [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate	2.50%
Line of Credit [Member] | Credit Facility [Member]
Debt Instrument, Term	5 years
Line of Credit Facility, Maximum Borrowing Capacity	$ 80
Line of Credit Facility, Additional Maximum Borrowing Capacity	100
Letter of Credit [Member] | Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 2.5

Note 5 - Long-term Debt - Compo

Note 5 - Long-term Debt - Components of Long-term Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Mar. 31, 2018
Long-term debt	$ 33,375
Less: discount	(312)	$ (365)
Less: current portion	(1,875)	(1,625)
Long-term portion	31,188	44,635
Line of Credit [Member]
Long-term debt	15,500	28,000
Term Loan [Member]
Long-term debt	$ 17,875	$ 18,625

Note 5 - Long-term Debt - Com_2

Note 5 - Long-term Debt - Components of Long-term Debt (Details) (Parentheticals)	Sep. 30, 2018
Line of Credit [Member]
Line of credit, interest rate at end of period	3.625%
Term Loan [Member]
Term loan, interest rate at end of period	3.75%

Note 5 - Long-term Debt - Futur

Note 5 - Long-term Debt - Future Contractual Maturities of Debt (Details) $ in Thousands	Sep. 30, 2018USD ($)
2,019	$ 875
2,020	2,125
2,021	2,625
2,022	27,750
Total	$ 33,375

Note 6 - Stock-based Compensa_3

Note 6 - Stock-based Compensation (Details Textual)	6 Months Ended
	Sep. 30, 2018$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	27,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares	$ 168.82
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period	2,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	24,940
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares	$ 53.56
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares	$ 143.36
Equity Plan 2014 [Member]
Common Stock, Capital Shares Reserved for Future Issuance	1,100,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	595,729
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	15,919
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares	$ 151.54
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	5 years
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period	1,720
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period	185
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	11,385
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares	$ 192.99
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	3 years
Performance Shares [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	0.00%
Performance Shares [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	400.00%
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	5 years

Note 6 - Stock-based Compensa_4

Note 6 - Stock-based Compensation - Allocation of Share-based Compensation (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Stock-based compensation expense	$ 990	$ 445	$ 1,729	$ 985
Amount of income tax expense (benefit) recognized in earnings	38	(108)	(858)	(120)
Stock-based compensation, net of tax	$ 1,028	$ 337	$ 871	$ 865
Basic (in dollars per share)	$ 0.27	$ 0.09	$ 0.23	$ 0.23
Diluted (in dollars per share)	$ 0.25	$ 0.09	$ 0.22	$ 0.22

Note 6 - Stock-based Compensa_5

Note 6 - Stock-based Compensation - Stock Option and Non-vested Stock Award Activity (Details)	6 Months Ended
	Sep. 30, 2018$ / sharesshares
Options outstanding (in shares)	458,000
Options outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 86.38
Non-vested stock awards outstanding (in shares)	9,000
Non-vested stock awards outstanding, weighted average grant date fair value (in dollars per share) | $ / shares	$ 125.68
Options granted (in shares)	24,940
Options granted, weighted average exercise price (in dollars per share) | $ / shares	$ 143.36
Non-vested stock awards granted (in shares)	27,000
Non-vested stock awards granted, weighted average grant date fair value (in dollars per share) | $ / shares	$ 168.82
Options forfeited or expired (in shares)	(25,000)
Options forfeited or expired, weighted average exercise price (in dollars per share) | $ / shares	$ 96.51
Non-vested stock awards forfeited (in shares)
Non-vested stock awards forfeited, weighted average grant date fair value (in dollars per share) | $ / shares	$ 142.20
Options exercised (in shares)	(52,000)
Options exercised, weighted average exercise price (in dollars per share) | $ / shares	$ 68.98
Non-vested stock awards vested (in shares)	(2,000)
Non-vested stock awards vested, weighted average grant date fair value (in dollars per share) | $ / shares	$ 151.18
Options outstanding (in shares)	406,000
Options outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 91.53
Non-vested stock awards outstanding (in shares)	34,000
Non-vested stock awards outstanding, weighted average grant date fair value (in dollars per share) | $ / shares	$ 161.30
Options exercisable (in shares)	157

Note 7 - Income Taxes (Details

Note 7 - Income Taxes (Details Textual) - USD ($) $ in Thousands	Dec. 22, 2017	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Mar. 31, 2019	Mar. 31, 2018
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	34.00%
Taxes Payable, Total							$ 220
Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability							(279)
Tax Adjustments, Settlements, and Unusual Provisions							$ (59)
Effective Income Tax Rate Reconciliation, Percent, Total		24.20%	23.90%	8.40%	12.20%
Scenario, Forecast [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent						21.00%

Note 8 - Earnings Per Share - C

Note 8 - Earnings Per Share - Computation of Net Income Per Share, Basic & Diluted (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Net income available for shareholders	$ 994	$ 2,353	$ 5,224	$ 3,870
Basic (in shares)	3,850	3,764	3,833	3,754
Dilutive effect of stock options (in shares)	188	171	183	180
Dilutive effect of non-vested shares (in shares)	8		13
Diluted (in shares)	4,046	3,935	4,029	3,934
Basic (in dollars per share)	$ 0.26	$ 0.63	$ 1.36	$ 1.03
Diluted (in dollars per share)	$ 0.25	$ 0.60	$ 1.30	$ 0.98

Note 8 - Earnings Per Share - A

Note 8 - Earnings Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Stock awards excluded from diluted EPS (in shares)	12	111	31	111
Stock Awards that were Antidilutive [Member]
Stock awards excluded from diluted EPS (in shares)	1	111	24	111
Stock Awards Subject to Performance Conditions [Member]
Stock awards excluded from diluted EPS (in shares)	11		7

Note 9 - Commitments and Cont_2

Note 9 - Commitments and Contingencies (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Litigation Settlement, Expense	$ 3,300		$ 3,300
Class Action In United States District Court [Member]
Litigation Settlement, Expense	$ 3,300

Note 10 - Segment Information_2

Note 10 - Segment Information (Details Textual) $ in Thousands	6 Months Ended
	Sep. 30, 2018USD ($)
Number of Reportable Segments	4
FRANCE
Long-Lived Assets	$ 6,203
CANADA
Long-Lived Assets	6,667
GERMANY
Long-Lived Assets	$ 15,585

Note 10 - Segment Information -

Note 10 - Segment Information - Operating Segment Information (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenues		$ 24,865	$ 22,954	$ 50,007	$ 45,627
Gross profit		14,577	13,233	29,668	25,904
Reconciling items	[1]	(13,271)	(10,127)	(23,962)	(21,495)
Earnings before income taxes		1,306	3,106	5,706	4,409
Sterilzation and Disinfection Control [Member]
Revenues		11,582	9,985	22,930	20,168
Gross profit		7,972	6,822	15,784	13,542
Reconciling items	[1]
Earnings before income taxes
Instruments [Member]
Revenues		8,704	7,983	17,435	16,586
Gross profit		5,354	4,963	10,987	9,871
Reconciling items	[1]
Earnings before income taxes
Cold Chain Monitoring [Member]
Revenues		2,950	3,151	6,173	6,068
Gross profit		1,164	1,193	2,628	2,087
Reconciling items	[1]
Earnings before income taxes
Cold Chain Packaging [Member]
Revenues		1,629	1,835	3,469	2,805
Gross profit		87	255	269	404
Reconciling items	[1]
Earnings before income taxes
[1]	Reconciling items include selling, general and administrative, research and development, and other expenses

Note 10 - Segment Information_3

Note 10 - Segment Information - Operating Segment Asset Reconciliation (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Mar. 31, 2018
Assets	$ 160,288	$ 164,101
Corporate, Non-Segment [Member]
Assets	14,905	9,283
Sterilzation and Disinfection Control [Member] | Operating Segments [Member]
Assets	77,817	83,452
Instruments [Member] | Operating Segments [Member]
Assets	30,616	33,479
Cold Chain Monitoring [Member] | Operating Segments [Member]
Assets	29,957	30,796
Cold Chain Packaging [Member] | Operating Segments [Member]
Assets	$ 6,993	$ 7,091

Note 10 - Segment Information_4

Note 10 - Segment Information - Revenues From External Customers (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenues	$ 24,865	$ 22,954	$ 50,007	$ 45,627
UNITED STATES
Revenues	16,617	14,432	32,165	27,443
Non-US [Member]
Revenues	$ 8,248	$ 8,522	$ 17,842	$ 18,184

Note 11 - Subsequent Event (Det

Note 11 - Subsequent Event (Details Textual) - Subsequent Event [Member]	1 Months Ended
	Oct. 31, 2018$ / shares
Common Stock, Dividends, Per Share, Declared	$ 0.16
Dividends Payable, Date to be Paid	Dec. 17, 2018
Dividends Payable, Date of Record	Nov. 30, 2018